首页> 美国卫生研究院文献>Journal of Virology >Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33 a Broadly Neutralizing Antibody
【2h】

Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33 a Broadly Neutralizing Antibody

机译:对丙型肝炎病毒疫苗:丙型肝炎病毒中和抗体AP33中和的结构基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is the principal target for neutralizing antibodies (NAbs). Most NAbs recognize hypervariable region 1 on E2, which undergoes frequent mutation, thereby allowing the virus to evade neutralization. Consequently, there is great interest in NAbs that target conserved epitopes. One such NAb is AP33, a mouse monoclonal antibody that recognizes a conserved, linear epitope on E2 and potently neutralizes a broad range of HCV genotypes. In this study, the X-ray structure of AP33 Fab in complex with an epitope peptide spanning residues 412 to 423 of HCV E2 was determined to 1.8 Å. In the complex, the peptide adopts a β-hairpin conformation and docks into a deep binding pocket on the antibody. The major determinants of antibody recognition are E2 residues L413, N415, G418, and W420. The structure is compared to the recently described HCV1 Fab in complex with the same epitope. Interestingly, the antigen-binding sites of HCV1 and AP33 are completely different, whereas the peptide conformation is very similar in the two structures. Mutagenesis of the peptide-binding residues on AP33 confirmed that these residues are also critical for AP33 recognition of whole E2, confirming that the peptide-bound structure truly represents AP33 interaction with the intact glycoprotein. The slightly conformation-sensitive character of the AP33-E2 interaction was explored by cross-competition analysis and alanine-scanning mutagenesis. The structural details of this neutralizing epitope provide a starting point for the design of an immunogen capable of eliciting AP33-like antibodies.
机译:丙型肝炎病毒(HCV)的E2包膜糖蛋白与宿主进入因子CD81结合,是中和抗体(NAb)的主要靶标。大多数NAb识别E2上的高变区1,该区域经常发生突变,从而使病毒逃避中和。因此,对靶向保守表位的NAb引起了极大的兴趣。一种此类NAb是AP33,一种小鼠单克隆抗体,可识别E2上保守的线性表位并有效中和多种HCV基因型。在这项研究中,AP33 Fab与覆盖HCV E2 412至423位残基的表位肽复合物的X射线结构确定为1.8。在复合物中,该肽采用β-发夹构象,并停靠在抗体上的深层结合袋中。抗体识别的主要决定因素是E2残基L413,N415,G418和W420。将结构与最近描述的具有相同表位的HCV1 Fab进行比较。有趣的是,HCV1和AP33的抗原结合位点完全不同,而两个结构中的肽构象却非常相似。对AP33上肽结合残基的诱变证实,这些残基对于AP33识别整个E2也是至关重要的,从而证实了肽结合的结构确实代表了AP33与完整糖蛋白的相互作用。通过交叉竞争分析和丙氨酸扫描诱变探讨了AP33-E2相互作用的轻微构象敏感性特征。该中和表位的结构细节为设计能够引发AP33样抗体的免疫原提供了起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号